Marshall Wace LLP Lowers Stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Marshall Wace LLP decreased its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 83.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,000 shares of the company's stock after selling 35,243 shares during the period. Marshall Wace LLP's holdings in Establishment Labs were worth $318,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its stake in Establishment Labs by 32,968.7% during the 1st quarter. BNP Paribas Financial Markets now owns 97,222 shares of the company's stock valued at $4,949,000 after acquiring an additional 96,928 shares in the last quarter. Stableford Capital II LLC purchased a new position in Establishment Labs during the first quarter worth about $1,568,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Establishment Labs in the 1st quarter worth about $4,185,000. Divisadero Street Capital Management LP bought a new stake in Establishment Labs in the 2nd quarter worth about $5,829,000. Finally, Principal Financial Group Inc. purchased a new stake in Establishment Labs in the 2nd quarter valued at about $593,000. Hedge funds and other institutional investors own 72.91% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Citigroup upped their target price on Establishment Labs from $45.00 to $50.00 and gave the company a "neutral" rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. decreased their target price on Establishment Labs from $61.00 to $50.00 and set an "overweight" rating for the company in a research report on Wednesday, August 7th. Finally, Stephens reiterated an "overweight" rating and set a $68.00 target price on shares of Establishment Labs in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Establishment Labs has a consensus rating of "Moderate Buy" and an average price target of $57.60.

Establishment Labs Stock Performance

NASDAQ:ESTA traded up $1.04 during trading hours on Friday, reaching $39.83. The stock had a trading volume of 414,906 shares, compared to its average volume of 379,205. The stock has a market cap of $1.11 billion, a P/E ratio of -12.81 and a beta of 1.20. The stock has a 50 day simple moving average of $42.46 and a 200 day simple moving average of $46.84. The company has a debt-to-equity ratio of 4.30, a quick ratio of 2.91 and a current ratio of 4.44. Establishment Labs Holdings Inc. has a 12-month low of $16.96 and a 12-month high of $60.12.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. The company had revenue of $44.12 million during the quarter, compared to analysts' expectations of $43.10 million. During the same quarter last year, the firm posted ($0.65) earnings per share. Establishment Labs's revenue for the quarter was down 9.2% compared to the same quarter last year. On average, research analysts forecast that Establishment Labs Holdings Inc. will post -2.27 EPS for the current fiscal year.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.